Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Edwards Lifesciences Stock Performance
Shares of NYSE:EW traded up $1.27 during trading on Friday, reaching $106.12. 2,033,510 shares of the company's stock traded hands, compared to its average volume of 2,478,073. The company has a debt-to-equity ratio of 0.10, a current ratio of 3.37 and a quick ratio of 2.60. Edwards Lifesciences has a 12 month low of $85.58 and a 12 month high of $131.73. The company has a 50 day moving average of $97.35 and a 200-day moving average of $105.27. The stock has a market capitalization of $65.79 billion, a P/E ratio of 45.94, a price-to-earnings-growth ratio of 3.09 and a beta of 1.12.
Edwards Lifesciences (NYSE:EW - Get Rating) last posted its earnings results on Thursday, July 28th. The medical research company reported $0.63 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.64 by ($0.01). The firm had revenue of $1.37 billion for the quarter, compared to analyst estimates of $1.40 billion. Edwards Lifesciences had a net margin of 27.18% and a return on equity of 24.77%. The company's revenue for the quarter was down .2% on a year-over-year basis. During the same period in the previous year, the firm earned $0.64 earnings per share. On average, equities analysts expect that Edwards Lifesciences will post 2.51 EPS for the current year.
Wall Street Analyst Weigh In
Several equities analysts recently weighed in on the stock. Cowen reduced their target price on shares of Edwards Lifesciences from $140.00 to $125.00 in a report on Monday, July 11th. Canaccord Genuity Group downgraded shares of Edwards Lifesciences from a "buy" rating to a "hold" rating and dropped their price target for the stock from $115.00 to $106.00 in a research note on Friday, July 29th. Stifel Nicolaus dropped their price target on shares of Edwards Lifesciences from $128.00 to $115.00 in a research note on Monday, July 18th. StockNews.com raised shares of Edwards Lifesciences from a "hold" rating to a "buy" rating in a research note on Friday. Finally, Truist Financial dropped their price target on shares of Edwards Lifesciences from $140.00 to $120.00 and set a "buy" rating on the stock in a research note on Wednesday, July 20th. Three research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the company. Based on data from MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $126.19.
Insider Buying and Selling at Edwards Lifesciences
In other Edwards Lifesciences news, VP Bernard J. Zovighian sold 4,811 shares of the business's stock in a transaction dated Friday, August 5th. The shares were sold at an average price of $103.66, for a total transaction of $498,708.26. Following the completion of the transaction, the vice president now directly owns 21,247 shares of the company's stock, valued at approximately $2,202,464.02. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other news, VP Daveen Chopra sold 1,000 shares of the company's stock in a transaction that occurred on Tuesday, August 2nd. The shares were sold at an average price of $102.49, for a total value of $102,490.00. Following the completion of the sale, the vice president now directly owns 18,911 shares of the company's stock, valued at approximately $1,938,188.39. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, VP Bernard J. Zovighian sold 4,811 shares of the company's stock in a transaction that occurred on Friday, August 5th. The stock was sold at an average price of $103.66, for a total transaction of $498,708.26. Following the completion of the sale, the vice president now directly owns 21,247 shares of the company's stock, valued at $2,202,464.02. The disclosure for this sale can be found here. Insiders sold 120,854 shares of company stock valued at $11,439,096 in the last ninety days. Company insiders own 1.29% of the company's stock.
